PRF Technologies

PRF Technologies Net Debt / EBITDA

The Net Debt to EBITDA of PRF Technologies (PRFX) as of Oct 28, 2026 is 0.83. In the previous year, Net Debt to EBITDA was 0.29 — a change of 189.27% (higher).

Net Debt / EBITDA

0.83

YoY

189.27%

Last updated:

Net Debt to EBITDA of PRF Technologies is 2025 0.83 . Net Debt to EBITDA of PRF Technologies was 2024 0.29 . It decreases by 189.27% higher compared to the previous year.

The PRF Technologies Net Debt / EBITDA history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Net Debt / EBITDA
Date
Net Debt / EBITDA
Jan 1, 2017
-4.00 USD
Jan 1, 2018
-8.96 USD
Jan 1, 2019
-7.59 USD
Jan 1, 2023
0.83 USD
Jan 1, 2024
0.29 USD
Jan 1, 2025
0.83 USD
The PRF Technologies Net Debt / EBITDA history
YEARNet Debt / EBITDAYoY
0.83+189.27%
0.29-65.32%
0.83-110.91%
-7.59-15.25%
-8.96+123.94%
-4.00—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

PRF Technologies Stock analysis

What does PRF Technologies do? PainReform Ltd. develops reformulated pain therapeutics to extend efficacy, minimize adverse effects, and improve patient convenience. The company focuses on enhancing established pharmaceuticals through its proprietary technology, targeting faster recovery of motor function. Its products are designed for healthcare providers and patients seeking advanced pain management solutions. The business model centers on licensing its reformulation technology to pharmaceutical partners. These partners integrate PainReform's solutions into their existing drug portfolios, leveraging the technology to improve product performance without developing new compounds from scratch. The primary buyers are established pharmaceutical companies looking to extend patent life and enhance market competitiveness of their pain management drugs. PainReform's technology addresses key pain management challenges by prolonging drug effects and reducing side effects. This positions the company as a strategic partner for pharmaceutical firms aiming to optimize their therapeutic offerings. The target segments include chronic pain patients and healthcare systems seeking more effective and safer pain treatment options. PRF Technologies is one of the most popular companies on Eulerpool.

Frequently Asked Questions about PRF Technologies stock

Net Debt to EBITDA of PRF Technologies is 0.83 in 2025.

Net Debt to EBITDA of PRF Technologies changed from 0.29 to 0.83, representing a 189.27% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Net Debt to EBITDA PRF Technologies since 2006 – with annual values, charts, and detailed analysis.

Net Debt/EBITDA measures how many years it would take to repay all debt using EBITDA. Lower ratios indicate stronger debt repayment capacity.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Net Debt to EBITDA's PRF Technologies with sector peers and the industry average to assess whether it is attractive.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Leverage — PRF Technologies

All Key Metrics — PRF Technologies